SCHEMBL24744499

SCHEMBL24744499

CCCC1CN(C(=O)CC)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 4/20 0.53
CHRNA3 P32297 4/20 0.53
CHRNA4 P43681 4/20 0.53
CHRNB3 Q05901 2/20 0.53
CHRNA6 Q15825 2/20 0.53
CHRNB4 P30926 2/20 0.52
CHRNA7 P36544 2/20 0.52
ALDH1A1 P00352 1/20 0.41
EPHX2 P34913 6/20 0.36
EPHX1 P07099 1/20 0.35
BLM P54132 1/20 0.34
POLB P06746 2/20 0.33
HPGD P15428 1/20 0.33
GNAI3 P08754 1/20 0.33
GNAO1 P09471 1/20 0.33
GNAI1 P63096 1/20 0.33
PKM P14618 1/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22765390 0.84 CHRNB2 (0.46) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL19703682 0.82 CHRNB2 (0.57) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL20937675 0.81 MEN1 (0.47) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL18059328 0.80 CHRNB2 (0.45) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL26159863 0.80 CHRNB2 (0.55) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL19405306 0.79 HPGD (0.49) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL4518519 0.79 GNAI3 (0.51) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL20808721 0.78 CYP2C9 (0.38) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL21277728 0.78 CHRNB2 (0.53) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL21765914 0.77 CHRNB2 (0.72) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022253713-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2022-12-08 WO disclosed